Jakob W. Gotfredsen

Nessuna posizione attualmente

Health Technology

Consumer Services

Commercial Services

Profilo

Jakob W.
Gotfredsen is the founder of Neurokey A, which was founded in 2007.
He held the title of Chief Business Officer from 2009 to 2010.
In 2004, he worked as a Product Manager at Roche Pharmaceuticals, Inc. until 2005.
Dr. Gotfredsen earned an MBA from the University of Copenhagen.

Precedenti posizioni note di Jakob W. Gotfredsen

Società	Posizione	Fine
Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	Fondatore	30/07/2010
Roche Pharmaceuticals, Inc. Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ.	Corporate Officer/Principal	01/01/2005

Vedi nel dettaglio l'esperienza di Jakob W. Gotfredsen

Formazione di Jakob W. Gotfredsen

University of Copenhagen

Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Jakob W. Gotfredsen

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	Health Technology
Roche Pharmaceuticals, Inc. Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ.	Commercial Services